PROGRAM / 01Monoclonal antibody
Immune-mediated kidney disease
Discovery stage; specific target and candidate mechanism are undisclosed.
02THERAPEUTIC R&D
ANTIBODY THERAPEUTICS
Antibody therapeutics
for kidney diseases
Podigy is advancing monoclonal and bispecific antibody candidates, with capabilities spanning candidate discovery, in-vitro assessment and in-vivo validation.
POD-BAB-01Bispecific antibody
Immune-mediated kidney disease
Discovery stage; specific target combination and candidate mechanism are undisclosed.
DISCLOSURE SCOPE
Progress-led disclosure
We currently disclose program type, indication and development stage. Targets, epitopes, structural designs and detailed mechanisms will be disclosed at appropriate milestones.
UndisclosedSpecific targets and detailed mechanisms of candidate molecules
Program status may change as R&D evaluations progress. This page does not constitute a performance claim for any candidate.